VERA Logo

Vera Therapeutics, Inc. (VERA) 

NASDAQ
Market Cap
$2.92B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
52 of 776
Rank in Industry
41 of 433

Largest Insider Buys in Sector

VERA Stock Price History Chart

VERA Stock Performance

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode …

Insider Activity of Vera Therapeutics, Inc.

Over the last 12 months, insiders at Vera Therapeutics, Inc. have bought $5M and sold $65.91M worth of Vera Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Vera Therapeutics, Inc. have bought $44.26M and sold $23.25M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Katabi Maha (director) — $10M.

The last purchase of 161,290 shares for transaction amount of $5M was made by Katabi Maha (director) on 2024‑01‑30.

List of Insider Buy and Sell Transactions, Vera Therapeutics, Inc.

2024-10-28Saledirector
15,000
0.0323%
$48.03$720,4930.00%
2024-10-23SalePRESIDENT AND CEO
19,375
0.0351%
$40.39$782,6100.00%
2024-10-09SalePRESIDENT AND CEO
15,625
0.0239%
$38.24$597,568+5.03%
2024-09-25SalePRESIDENT AND CEO
22,225
0.0419%
$46.02$1.02M-0.77%
2024-09-19Saledirector
13,823
0.0254%
$42.31$584,793-2.30%
2024-09-18Saledirector
2,653
0.005%
$42.01$111,440+2.06%
2024-09-11SalePRESIDENT AND CEO
15,625
0.0285%
$37.50$585,9340.00%
2024-08-28SalePRESIDENT AND CEO
30,320
0.0555%
$36.84$1.12M+9.73%
2024-08-21SalePRESIDENT AND CEO
14,471
0.0263%
$39.76$575,425+0.40%
2024-08-14SalePRESIDENT AND CEO
15,625
0.03%
$37.56$586,9270.00%
2024-05-16SaleSVP, FINANCE, CHIEF ACCT OFFCR
20,651
0.037%
$42.32$873,890-8.40%
2024-05-15SaleSVP, FINANCE, CHIEF ACCT OFFCR
10,186
0.0184%
$42.27$430,546-10.10%
2024-04-10SaleSVP, FINANCE, CHIEF ACCT OFFCR
5,714
0.01%
$40.00$228,560-5.33%
2024-04-03SaleCHIEF FINANCIAL OFFICER
118,477
0.2156%
$39.58$4.69M-0.98%
2024-03-25Saledirector
340,000
0.6089%
$40.50$13.77M-4.16%
2024-03-22Saledirector
413,450
0.7439%
$40.51$16.75M-3.73%
2024-03-21Saledirector
81,009
0.1521%
$44.20$3.58M-7.88%
2024-01-30Purchasedirector
161,290
0.3273%
$31.00$5M+15.81%
2024-01-10Sale10 percent owner
1.05M
2.1892%
$18.00$18.9M+103.22%
2023-08-21SalePresident and CEO
5,210
0.0108%
$16.66$86,779+95.17%

Insider Historical Profitability

73.8%
COMMODORE CAPITAL LP10 percent owner
4400000
7.1002%
$47.1111+20.13%
Katabi Mahadirector
2793987
4.5086%
$47.1123+57.41%
SEIDENBERG BETH Cdirector
131553
0.2123%
$47.11193+96.5%
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR
51206
0.0826%
$47.1123+91.54%
Grant SeanCHIEF FINANCIAL OFFICER
0
0%
$47.1141+32.83%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Avoro Capital Advisors Llc$227.03M9.635.26MNew+$227.03M2.72
BlackRock$143.11M6.073.32M+20.48%+$24.32M<0.01
Commodore Capital, LP$136.47M5.793.17M-41.93%-$98.53M0.52
Fidelity Investments$134.68M5.713.12M+12.58%+$15.04M0.01
Sofinnova$120.48M5.112.79M-19.42%-$29.03M0.25
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.